Related Experiment Video
Updated: Nov 18, 2025
12:40
Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
Published on: April 6, 2015
18.9K
When Secretomes Meet Anthelmintics: Lessons for Therapeutic Interventions
Yovany Moreno1, Timothy G Geary2, Lucienne Tritten3
1Boehringer-Ingelheim Animal Health, Duluth, GA, USA.
Trends in Parasitology
|February 10, 2021
Summary
Helminth parasites release molecules that modulate host immunity. Understanding these parasite-derived molecules (PDMs) and their suppression by drugs could lead to new anthelmintic strategies.
Area of Science:
- Immunoparasitology
- Pharmacology
- Molecular Biology
Background:
- Helminth secretomes contain diverse immunomodulatory molecules.
- Parasite-derived molecules (PDMs) are crucial for host establishment and persistence.
- The mechanisms of action for benzimidazole and macrocyclic lactone anthelmintics are not fully understood, though PDM release is suppressed.
Purpose of the Study:
- To explore the role of PDMs in host-parasite interactions.
- To investigate the impact of anthelmintic drugs on PDM release.
- To propose novel anthelmintic strategies by integrating immunoparasitology and pharmacology.
Main Methods:
- Literature review integrating immunoparasitology and pharmacology research.
- Analysis of known helminth secretome components and their functions.
- Hypothesizing mechanisms of anthelmintic drug action related to PDM suppression.
Main Results:
- Helminth secretomes are rich in molecules that influence host immune responses.
- PDMs are key mediators for parasites to maintain infection.
- Anthelmintic drugs like benzimidazoles and macrocyclic lactones inhibit PDM release.
Conclusions:
- Understanding PDMs is vital for comprehending host-parasite dynamics.
- Targeting PDM release presents a promising avenue for novel anthelmintic drug development.
- Interdisciplinary research combining immunoparasitology and pharmacology can advance anthelmintic strategies.
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
5.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
5.8K
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
463
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
463
01:17Drugs for Treatment of Diarrhea-Predominant IBS
424
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
424
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.2K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
621
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
621
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
428
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
428